These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9869614)

  • 1. Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects.
    Poo JL; Jiménez W; María Muñoz R; Bosch-Marcé M; Bordas N; Morales-Ruiz M; Pérez M; Deulofeu R; Solé M; Arroyo V; Rodés J
    Gastroenterology; 1999 Jan; 116(1):161-7. PubMed ID: 9869614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.
    Cavasin MA; Semus H; Pitts K; Peng Y; Sandoval J; Chapo J; Plato CF
    Can J Physiol Pharmacol; 2010 Jun; 88(6):636-43. PubMed ID: 20628429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.
    Feng HQ; Weymouth ND; Rockey DC
    Am J Physiol Gastrointest Liver Physiol; 2009 Jul; 297(1):G27-33. PubMed ID: 19299580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo.
    Kojima H; Sakurai S; Kuriyama S; Yoshiji H; Imazu H; Uemura M; Nakatani Y; Yamao J; Fukui H
    J Hepatol; 2001 Jun; 34(6):805-11. PubMed ID: 11451162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance.
    Kojima H; Yamao J; Tsujimoto T; Uemura M; Takaya A; Fukui H
    J Hepatol; 2000 Jan; 32(1):43-50. PubMed ID: 10673066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of endothelin A receptor antagonist on hepatic hemodynamics in cirrhotic rats. Implications for endothelin-1 in portal hypertension.
    Takashimizu S; Kojima S; Nishizaki Y; Kagawa T; Shiraishi K; Mine T; Watanabe N
    Tokai J Exp Clin Med; 2011 Jul; 36(2):37-43. PubMed ID: 21769771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis.
    Cho JJ; Hocher B; Herbst H; Jia JD; Ruehl M; Hahn EG; Riecken EO; Schuppan D
    Gastroenterology; 2000 Jun; 118(6):1169-78. PubMed ID: 10833492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
    Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
    Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
    Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
    J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes enhances the intrahepatic vascular response to endothelin-1 in cirrhotic rats: association with the ETA receptor and pERK up-regulation.
    Lee JY; Lee FY; Huo TI; Wang SS; Huang HC; Lin HC; Chuang CL; Lee SD
    Liver Int; 2015 Mar; 35(3):704-12. PubMed ID: 24636620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of endothelin-1 on portal-systemic collaterals of common bile duct-ligated cirrhotic rats.
    Chan CC; Wang SS; Lee FY; Chang FY; Lin HC; Hou MC; Huang HC; Lee SD
    Eur J Clin Invest; 2004 Apr; 34(4):290-6. PubMed ID: 15086361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paracrine renal endothelin system in rats with liver cirrhosis.
    Hocher B; Zart R; Diekmann F; Rohmeiss P; Distler A; Neumayer HH; Bauer C; Gross P
    Br J Pharmacol; 1996 May; 118(2):220-7. PubMed ID: 8735618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An endothelin receptor antagonist TAK-044 ameliorates carbon tetrachloride-induced acute liver injury and portal hypertension in rats.
    Gandhi CR; Nemoto EM; Watkins SC; Subbotin VM
    Liver; 1998 Feb; 18(1):39-48. PubMed ID: 9548266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats.
    Thirunavukkarasu C; Yang Y; Subbotin VM; Harvey SA; Fung J; Gandhi CR
    Gut; 2004 Jul; 53(7):1010-9. PubMed ID: 15194653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of platelet activating factor and its antagonist on portal hypertension associated with liver cirrhosis: an experiment with rats].
    Wang CP; Han J; Ma XM; Dong K; Xiang Y; Su SH; Feng YY; Yang YP
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3337-41. PubMed ID: 16409839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ablation of primary afferent neurons by neonatal capsaicin treatment reduces the susceptibility of the portal hypertensive gastric mucosa to ethanol-induced injury in cirrhotic rats.
    Camara PR; Ferraz GJ; Franco-Penteado CF; Sbragia-Neto L; Meirelles LR; Teixeira SA; Muscara MN; Velloso LA; Antunes E; Ferraz JG
    Eur J Pharmacol; 2008 Jul; 589(1-3):245-50. PubMed ID: 18555214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
    Sogni P; Moreau R; Gomola A; Gadano A; Cailmail S; Calmus Y; Clozel M; Lebrec D
    Hepatology; 1998 Sep; 28(3):655-9. PubMed ID: 9731554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin 1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites.
    Leivas A; Jiménez W; Lamas S; Bosch-Marcé M; Oriola J; Clària J; Arroyo V; Rivera F; Rodés J
    Gastroenterology; 1995 Jun; 108(6):1842-8. PubMed ID: 7768391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
    J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.